A clinical trial to study effect of Allogenic human pulp derived mesenchymal stem cells in patients with intrabony defects
Phase 1
Not yet recruiting
- Registration Number
- CTRI/2018/02/011734
- Lead Sponsor
- Harini Mitta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Systemically healthy patients with diagnosed to have chronic periodontitis with atleast one intrabony defect with defect depth >= 3mm
2) probing depth >= 5mm
Exclusion Criteria
1)Patients having systemic diseases
2)History of antibiotics use in the past 6 months
3)Previous periodontal surgeries within 1 year on study tooth
4)Pregnant and lactating mothers
Smokers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Increase in linear bone growth and % bone fillTimepoint: baseline and 6 months
- Secondary Outcome Measures
Name Time Method clinical attachment level gain and probing depth reductionTimepoint: baseline and 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which allogenic human pulp-derived mesenchymal stem cells promote bone regeneration in intrabony defects?
How does the combination of allogenic human pulp-derived mesenchymal stem cells and beta-tricalcium phosphate compare to standard bone grafting materials in treating intrabony defects?
Which biomarkers are associated with successful engraftment and therapeutic response to allogenic human pulp-derived mesenchymal stem cells in periodontal regeneration?
What are the potential adverse events and safety management strategies for allogenic human pulp-derived mesenchymal stem cell therapy in intrabony defect treatment?
Are there any related compounds or combination therapies that enhance the osteogenic potential of beta-tricalcium phosphate in intrabony defect repair?